Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

BioLineRx Ltd (BLRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow BioLineRx's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.680 -0.130    -7.18%
15:59:59 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US09071M2052 
CUSIP:  09071M205
  • Volume: 277,879
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.670 - 1.830
BioLineRx 1.680 -0.130 -7.18%
Name Company Industry
   
P/E Ratio TTM - 34.98
Price to Sales TTM - 844.36
Price to Cash Flow MRQ - 58.4
Price to Free Cash Flow TTM - 27.19
Price to Book MRQ 1.14 8.65
Price to Tangible Book MRQ 1.75 7.48
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM - 76.86
Gross Margin 5YA - 79.66
Operating margin TTM - -8,765.18
Operating margin 5YA - -1,114.13
Pretax margin TTM - -8,677.71
Pretax margin 5YA - -1,084.09
Net Profit margin TTM - -8,679.27
Net Profit margin 5YA - -1,042.67
   
Revenue/Share TTM - 26.57
Basic EPS ANN -1.78 3.15
Diluted EPS ANN -1.78 3.01
Book Value/Share MRQ 1.59 23.29
Tangible Book Value/Share MRQ 1.12 1.89
Cash/Share MRQ 1.41 14.35
Cash Flow/Share TTM -1.07 9.13
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM -65.24% 9.75
Return on Equity 5YA - 393.24
Return on Assets TTM -46.62% 0.84
Return on Assets 5YA - -4.63
Return on Investment TTM -54.84% 8.33
Return on Investment 5YA - -5.66
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 66.71% 86.09
EPS(TTM) vs TTM 1 Yr. Ago TTM 47.98% 93.93
5 Year EPS Growth 5YA - -1.89
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ - 863.9
Sales (TTM) vs TTM 1 Yr. Ago TTM - 709.34
5 Year Sales Growth 5YA - 28.47
5 Year Capital Spending Growth 5YA - 24.73
   
Quick Ratio MRQ - 2.52
Current Ratio MRQ 6.76 4.88
LT Debt to Equity MRQ 3.66% 169.81
Total Debt to Equity MRQ 8.44% 187.32
Efficiency    
Asset Turnover TTM - 0.43
Inventory Turnover TTM - 3.56
Revenue/Employee TTM - 1.68M
Net Income/Employee TTM - 312.76K
Receivable Turnover TTM - 47.38
   
Dividend Yield ANN - 4.07
Dividend Yield 5 Year Avg. 5YA - 3.46
Dividend Growth Rate ANN - 16.94
Payout Ratio TTM - 52.48
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BLRX Comments

Write your thoughts about BioLineRx Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Neta Goldberg
Neta Goldberg Jul 06, 2021 7:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They get fda fast track!!!
Greg Heal
Greg Heal Jul 01, 2021 10:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now it looks like my lucky ticket to the moon 🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝
Vitor Bdo
Vitor Bdo Jun 30, 2021 4:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Get ready for the plane's take-off.
Samir Naik
Samir Naik May 14, 2021 5:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I will not be a surprise, if this stock goes with 3 digit figures in the long run. lots of potential is hidden and should bustout anytime.
Samir Naik
Samir Naik May 14, 2021 5:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
journey begins...
Zoran Labus
Zoran Labus May 12, 2021 6:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.tipranks.com/stocks/blrx/forecast
mordecai nadav
mordecai nadav May 07, 2021 9:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do they really had good results ?The stock behavior say otherwise
MR Hunter
MR Hunter May 06, 2021 3:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
they will file for approval early next year, hopefully this will help it pick up again
Tariq Matloob
Tariq Matloob May 04, 2021 11:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment
Dong ThreeThousand
Dong ThreeThousand May 04, 2021 11:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any chance that the result was overrated? How is us market reacting to the results?
Benjamin Kumpfmueller
Benjamin Kumpfmueller May 04, 2021 11:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Moshe Ohr
Moshe Ohr May 04, 2021 11:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If so this can hit $30 with ease
Giuseppe Giannachi
Giuseppe Giannachi May 04, 2021 9:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Only me?
Dong ThreeThousand
Dong ThreeThousand May 04, 2021 9:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What r the reactions to the news? On US?
Giuseppe Giannachi
Giuseppe Giannachi May 04, 2021 9:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
D*mn! Site frozen
Katona Örs
Katona Örs May 04, 2021 8:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news??
Samir Naik
Samir Naik Apr 12, 2021 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BLRX should be back in force from May 20th...keep holding, keep accommodating and keep patience. Price below 3 will be a dream later! Research and approvals is a long-term process...
Khembo Volev
Khembo Volev Apr 12, 2021 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Samir you're breaking the car
Luca Lanzoni
Luca Lanzoni Mar 11, 2021 9:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BIOLINERX LTD.   NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON APRIL 5, 2021  Whtat are you toughts?
Spike Trademark
Spike Trademark Mar 04, 2021 4:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going long, already up quite a bit and it is a lonely green island in a sea of red today.
Luca Lanzoni
Luca Lanzoni Mar 04, 2021 4:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i was says the same before this big pull back, do you have any ideas news of the highest pt soon?
Luca Lanzoni
Luca Lanzoni Mar 03, 2021 1:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello Neta, what do you think about BLRX? i am still holding long and strong
Neta Goldberg
Neta Goldberg Feb 23, 2021 3:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Upcoming Significant Expected MilestonesTop-line results from the Phase 3 GENESIS trial in SCM in early Q2 2021.Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of 2021.Pre-NDA meeting with the FDA for SCM in the second half of 2021NDA submission for SCM in the first half of 2022
Neta Goldberg
Neta Goldberg Feb 23, 2021 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Announced positive results from an interim analysis of its GENESIS Phase 3 trial of motixafortide in stem-cell mobilization (SCM). The interim analysis found statistically significant evidence for the primary endpoint favoring treatment with motixafortide. Based on a recommendation from the independent Data Monitoring Committee (DMC), enrollment was ceased early at 122 patients (instead of 177 originally planned), and top-line data, including full primary and secondary efficacy endpoints, is anticipated in early second quarter of 2021. In parallel, the Company is proceeding with all activities in support of an NDA submission in this indication anticipated in the first half of 2022, including a pre-NDA meeting with the FDA planned for the second half of 2021.
Luca Lanzoni
Luca Lanzoni Feb 22, 2021 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news on BLRX?
Neta Goldberg
Neta Goldberg Feb 22, 2021 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No :( patience but slowly i lost the believe on this stock!
Luca Lanzoni
Luca Lanzoni Feb 22, 2021 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Neta Goldberg  thank you Neta, I think we have to keep the faith, I am holding long and strong BLRX or we made a mistake to not sell it at 4.25 weeks ago
Spike Trademark
Spike Trademark Feb 17, 2021 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Green island in a sea of red today.
Moshe Ohr
Moshe Ohr Feb 17, 2021 8:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looks like an opportunity
Neta Goldberg
Neta Goldberg Feb 16, 2021 1:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BLRX, EXPECT VERY GOOD NEWS TO ME FDA PHASE 3 OF MEDICATION, SO TIPRANKSThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech. ”
Luca Lanzoni
Luca Lanzoni Feb 16, 2021 1:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thank you to share Neta, I am holding BLRX long and strong
Neta Goldberg
Neta Goldberg Feb 16, 2021 1:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will surely be up soon again. Small bumps are expected. Then it will ramp again, and if more positive news hits then it will sharply ascend.
Neta Goldberg
Neta Goldberg Feb 12, 2021 1:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When is the fda approval?
Samir Naik
Samir Naik Feb 06, 2021 7:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BLRX long term range intervals looks like: 5-12-22-50-70-100+
Samir Naik
Samir Naik Feb 06, 2021 7:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BLRX should be back in force from May 20th...keep holding, keep accommodating and keep patience. Price below 3 will be a dream later! Research and approvals is a long-term process...
Spyr Nik
Spyr Nik Feb 05, 2021 10:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any comments?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email